GlassScriptPhysician profile
Myriam Guevara
NPI 1467604348
$11,517.70
in general payments reported to CMS, 2019-2025
31 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,441 · 2020: $3,825 · 2021: $68.13 · 2022: $883 · 2023: $1,090 · 2024: $1,092 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.83 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,220.01 | 2019-2025 | Benlysta, Nucala |
| Abbvie INC. | $1,722.33 | 2019-2025 | |
| Janssen Biotech, INC. | $1,382.69 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $677.83 | 2019-2025 | |
| Amgen INC. | $597.38 | 2019-2025 | Tavneos, Otezla, Enbrel |
| Ucb, INC. | $258.00 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $236.75 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $187.80 | 2019 | |
| Aurinia Pharma U.S., INC. | $150.14 | 2024-2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $142.65 | 2019 | |
| Lilly USA, LLC | $135.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.65 | 2021-2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $113.52 | 2024-2025 | Idacio, Stimufend, Tyenne |
| Celgene Corporation | $85.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $75.64 | 2019-2025 | Orencia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $71.34 | 2023 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $57.63 | 2022-2024 | Cuvitru |
| Kiniksa Pharmaceuticals International, Plc | $39.89 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $26.61 | 2024 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2019 | |
| Grifols USA, LLC | $25.10 | 2024 | Xembify |
| Csl Behring | $22.70 | 2024 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2023 | |
| Horizon Therapeutics Plc | $16.59 | 2023 | Krystexxa |
| Genzyme Corporation | $16.45 | 2021 | |
| Biocryst US Sales Co., LLC | $15.86 | 2024 | Orladeyo |
| Kiniksa Pharmaceuticals, LTD. | $15.80 | 2023 | Arcalyst |
| Bioventus LLC | $15.12 | 2019 | |
| Antares Pharma, INC. | $15.09 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $14.92 | 2019 | |
| Qiagen, LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myriam Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.